Progenics Pharmaceuticals to Host Conference Call to Review Third Quarter
Financial Results on November 8
TARRYTOWN, N.Y., Nov. 2, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,
Inc. (Nasdaq:PGNX) announced today that it will host a conference call and
webcast to discuss its financial results for the third quarter on Thursday,
November 8, 2012 at 8:30 a.m. EST.
To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001
(international) and reference conference ID 58519374. A live webcast will be
available on the Events section of the Progenics website, www.progenics.com,
and a replay will be available on the website for two weeks.
Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical
company dedicated to the development of innovative medicines to treat disease,
with a focus on cancer and related conditions. Progenics' pipeline candidates
include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2
testing for treatment of prostate cancer, and preclinical stage novel
multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of
cancer. Progenics has exclusively licensed development and commercialization
rights for its first commercial product, RELISTOR^®, to Salix Pharmaceuticals,
Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co.,
Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR
(methylnaltrexone bromide) subcutaneous injection is a first-in-class
treatment for opioid-induced constipation approved in more than 50 countries
for patients with advanced illness.
The Progenics Pharmaceuticals Inc. logo is available at
CONTACT: Amy Martini
Press spacebar to pause and continue. Press esc to stop.